title: PSA Decrease with Fulvestrant Acetate in a Hormone-Resistant Metastatic Prostate Cancer Patient: A Case Report.
abstract: Metastatic prostate cancer is an incurable disease. After a period of hormone sensitivity that allows for the use of antiandrogens, the disease invariably progresses to a situation of androgen-independent growth, which deserves the consideration or the use of chemotherapy. As many of these patients are elderly and fragile, treatment with chemotherapy is challenging. Therefore, new drugs are required. Preclinical evidence supports the role of estrogen receptor (ER) signaling in prostate cancer. In this paper, we report the first published evidence of PSA control in a patient with metastatic prostate cancer treated with fulvestrant acetate.
authors.affiliation: Department of Medical Oncology, Hospital de Dènia, Marina Salud, Dénia, Spain.
authors.forename: Joan Manel
authors.initials: JM
authors.lastname: Gasent Blesa
authors.forename: Vicente
authors.initials: V
authors.lastname: Alberola Candel